Of the twenty-seven biopharma royalty transactions executed in 2025, one had venture investors writing into the syndicate. Castle Creek Biosciences, February 25, 2025. Ligand wrote $50 million, three co-investors wrote $25 million, the royalty paid high-single-digit on worldwide D-Fi sales. Two of those three co-investors were existing equity holders in

W20 at a glance Window (Sun May 10 – Fri May 15): ~$9.15B in disclosed actual upfront cash committed; up to ~$18.1B in contingent milestones and CVRs separately. Actual upfront cash, ~$9.15B: * M&A upfronts, ~$6.29B: $5.3B Biogen / Apellis + $650M Collegium / Corium + $166.4M Zydus

When a generic manufacturer files a Paragraph IV certification against an Orange Book-listed patent, or when a hedge fund petitions the PTAB for inter partes review of a composition-of-matter claim, the immediate question for every royalty holder in the capital stack is existential: does the royalty survive? The answer is

Innovo Therapeutics Inc. is a Seoul-based private biotechnology company developing small-molecule therapeutics across inflammatory immune disease, fibrosis, and oncology. Discovery and lead optimisation are conducted on a proprietary AI-augmented computational platform branded DeepZema®. The company was founded in 2019 by Hee-Dong Park, a former LG Chem drug-discovery executive, and operates

What is Coefficient Giving? Coefficient Giving is a San Francisco-based philanthropic funder and advisor that recommends and administers grants on behalf of major donors pursuing what it calls cost-effective, high-impact giving. Until November 2025, the organisation was known as Open Philanthropy. The name change formalised a strategic shift toward operating

Co-promotion rights are the most consistently underestimated provision in pharmaceutical license agreements. They sit innocuously in the term sheet as a one-line option held by the licensor, often free, often "subject to mutually agreed terms." When exercised, they restructure the entire economic profile of the contract: the US

A pharmaceutical right, once licensed, comes home through a dozen distinct mechanisms operated by five distinct buyer archetypes. The same legal instrument (an Asset Purchase Agreement, a Termination Agreement, a contractual reversion clause) means very different things depending on whether a Phase-3-failed asset is being salvaged by its original developer,

In April 2022, a Texas jury needed two hours to decide that Daiichi Sankyo owed Seagen $41.8 million in back royalties on Enhertu — plus an 8% running rate on all future US sales of what was already a multi-billion dollar oncology franchise. Three years later, the Federal Circuit reversed

W19 at a glance Window: Sun May 3 – Fri May 8, 2026. ~$17.95B committed deal value + up to $5.5B contingent + ~$3.2B fresh biotech equity / structured capital. Headline events: $6.7B Merck/Terns close (Tue); $4.1B Angelini/Catalyst (Thu); $1.05B Roche/PathAI (Thu); $1.0B Phoenix